Stifel analyst Daniel Arias maintains $Bruker Corp (BRKR.US)$ with a hold rating, and adjusts the target price from $77 to $70.
According to TipRanks data, the analyst has a success rate of 40.6% and a total average return of -8.6% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Bruker Corp (BRKR.US)$'s main analysts recently are as follows:
Bruker experienced continued softness in China and in the biopharmaceutical sector during the quarter, as observed by the analyst.
The company experienced challenging results within a difficult macroeconomic context, according to an analyst. Adjustments to estimates have been made reflecting reduced fiscal 2024 targets. Nonetheless, it is believed that the company's strong positioning in multi-omics and materials sciences will allow it to capitalize on the anticipated demand resurgence in biopharma and China.
Bruker's third-quarter results did not meet expectations, and the company has revised its organic sales growth forecast for fiscal 2024 downward, attributing this adjustment to a more gradual recovery in China and early-stage growth in the biopharma sector. The revision in guidance is explained not by a significant downturn in Q3 markets but by previous forecasts that were perhaps too optimistic. Nevertheless, the company's management conveyed an optimistic outlook for 2025.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
斯迪富分析師Daniel Arias維持$布魯克 (BRKR.US)$持有評級，並將目標價從77美元下調至70美元。
根據TipRanks數據顯示，該分析師近一年總勝率為40.6%，總平均回報率為-8.6%。
此外，綜合報道，$布魯克 (BRKR.US)$近期主要分析師觀點如下：
Bruker在本季度在中國和生物製藥板塊經歷持續疲軟，這一點被分析師觀察到。
據一位分析師稱，該公司在困難的宏觀經濟環境中經歷了具有挑戰性的業績。 對2024財年目標的調整已經反映出了降低的預期。儘管如此，人們相信該公司在多組學和材料科學領域的強勢定位將使其能夠利用預期的生物製藥和中國市場需求復甦。
Bruker的第三季度業績沒有達到預期，並且該公司已經下調了2024財年有機銷售增長預期，將此調整歸因於中國的復甦較爲緩慢和生物製藥板塊的初期增長。 對指引的修訂並不是由於Q3市場出現顯著下滑，而是由先前的預測可能過於樂觀。 儘管如此，該公司管理層對2025年表示了樂觀的展望。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
